![Final Results from the Longest Hereditary Angioedema Study of Active Treatment Duration Conducted to Date Support the Sustained Safety and Efficacy of TAKHZYRO® (lanadelumab) Injection for Long-Term Prevention of Hereditary Angioedema Attacks Final Results from the Longest Hereditary Angioedema Study of Active Treatment Duration Conducted to Date Support the Sustained Safety and Efficacy of TAKHZYRO® (lanadelumab) Injection for Long-Term Prevention of Hereditary Angioedema Attacks](https://mms.businesswire.com/media/20210805005209/en/731159/23/TakedaBrandSymbol_Dakiyama_Rd.jpg)
Final Results from the Longest Hereditary Angioedema Study of Active Treatment Duration Conducted to Date Support the Sustained Safety and Efficacy of TAKHZYRO® (lanadelumab) Injection for Long-Term Prevention of Hereditary Angioedema Attacks
Takeda launches CINRYZE™ in India, the first C1-I NH for prophylaxis in hereditary angioedema patients
![Successful Long-Term Prophylactic Treatment With Subcutaneous C1 Esterase Inhibitor in a Patient With Hereditary Angioedema - Janina Hahn, Melanie Nordmann-Kleiner, Susanne Trainotti, Thomas K. Hoffmann, Jens Greve, 2020 Successful Long-Term Prophylactic Treatment With Subcutaneous C1 Esterase Inhibitor in a Patient With Hereditary Angioedema - Janina Hahn, Melanie Nordmann-Kleiner, Susanne Trainotti, Thomas K. Hoffmann, Jens Greve, 2020](https://journals.sagepub.com/cms/10.1177/0897190019857407/asset/images/large/10.1177_0897190019857407-fig1.jpeg)
Successful Long-Term Prophylactic Treatment With Subcutaneous C1 Esterase Inhibitor in a Patient With Hereditary Angioedema - Janina Hahn, Melanie Nordmann-Kleiner, Susanne Trainotti, Thomas K. Hoffmann, Jens Greve, 2020
![Recombinant replacement therapy for hereditary angioedema due to C1 inhibitor deficiency | Immunotherapy Recombinant replacement therapy for hereditary angioedema due to C1 inhibitor deficiency | Immunotherapy](https://www.futuremedicine.com/cms/10.2217/imt.15.44/asset/images/medium/figure1.gif)